Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tetra Discovery Partners LLC

Capping PDE4 enzymes to treat memory loss, depression

This article was originally published in Start Up

Executive Summary

Mark Gurney, one of the scientists credited with discovering the gene for beta-secretase, was surprised and disappointed when beta-amyloid antibodies failed to help Alzheimer’s disease patients, but he believes he has found an approach that will work: a mechanistically novel way of selectively inhibiting specific forms of PDE4. This is a bold bet for his start-up Tetra Discovery Partners LLC to pursue, given how grievously many major drugmakers failed in earlier efforts to inhibit PDE4.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC092419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel